Bullous pemphigoid associated with the use of DPP4 inhibitors: A case series

Manali Saha; Mriganka Bandyopadhyay; Ananya Mandal; Arijit Ghosh; Pragnadyuti Mandal; Suman Chattopadhyay

doi:10.5455/njppp.2024.14.12587202316032024

2024, Vol: 14, Issue: 5

14 / 5Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Authorship Declaration

« Previous Article

Case Series

Online Publishing Date:
02 / 04 / 2024

Natl J Physiol Pharm Pharmacol. 2024; 14(9):

doi: 10.5455/njppp.2024.14.12587202316032024

Bullous pemphigoid associated with the use of DPP4 inhibitors: A case series

Manali Saha, Mriganka Bandyopadhyay, Ananya Mandal, Arijit Ghosh, Pragnadyuti Mandal, Suman Chattopadhyay.

Abstract
Dipeptidyl-peptidase 4 (DPP-4) inhibitors are one of the most commonly used anti-diabetic drugs because of their established safety and efficacy. Bullous pemphigoid which is an autoimmune blister skin disorder associated with DPP-4 inhibitors is a recognized adverse drug reaction (ADR) reported in some Southeast Asian Nations but has not been reported earlier from India. It is an uncommon, serious treatment with emergent adverse effects. Here, we report a series of five cases of DPP-4 inhibitor Linagliptin-induced bullous pemphigoid reaction in Type 2 diabetes mellitus patients. We are reporting five cases that showed various clinical manifestations in terms of gender (males 4), duration of diabetes (average 7.2 years), glycemic control (average HbA1C 6.7%), and latency period (average 3.6 weeks) for development of the ADR. Quality of life and treatment satisfaction were severely impacted by this ADR. Withdrawal of Linagliptin, use of topical and oral steroids and immunosuppressant like azathioprine were prescribed and effective for improving the lesions of all the cases. As per the World Health Organization-Uppsala Monitoring Center scale, causality was established as “probable” for all the cases. This case series serves to bring to the notice of prescribers regarding this important cutaneous ADR with the use of Linagliptin. This case intends to improve awareness among clinicians regarding the possibility of this cutaneous ADR among diabetic patients to facilitate early diagnosis and intervention.

Key words: Bullous Pemphigoid; Linagliptin; Teneligliptin; DPP4 Inhibitors; Diabetes Mellitus; Adverse Drug Reaction; Pharmacovigilance

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Manali Saha Articles by Mriganka Bandyopadhyay Articles by Ananya Mandal Articles by Arijit Ghosh Articles by Pragnadyuti Mandal Articles by Suman Chattopadhyay
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Saha M, Bandyopadhyay M, Mandal A, Ghosh A, Mandal P, Chattopadhyay S. Bullous pemphigoid associated with the use of DPP4 inhibitors: A case series. Natl J Physiol Pharm Pharmacol. Online First: 02 Apr, 2024. doi:10.5455/njppp.2024.14.12587202316032024

Web Style

Saha M, Bandyopadhyay M, Mandal A, Ghosh A, Mandal P, Chattopadhyay S. Bullous pemphigoid associated with the use of DPP4 inhibitors: A case series. https://www.njppp.com/?mno=183062 [Access: April 05, 2024]. doi:10.5455/njppp.2024.14.12587202316032024

AMA (American Medical Association) Style

Saha M, Bandyopadhyay M, Mandal A, Ghosh A, Mandal P, Chattopadhyay S. Bullous pemphigoid associated with the use of DPP4 inhibitors: A case series. Natl J Physiol Pharm Pharmacol. Online First: 02 Apr, 2024. doi:10.5455/njppp.2024.14.12587202316032024

Vancouver/ICMJE Style

Saha M, Bandyopadhyay M, Mandal A, Ghosh A, Mandal P, Chattopadhyay S. Bullous pemphigoid associated with the use of DPP4 inhibitors: A case series. Natl J Physiol Pharm Pharmacol, [cited April 05, 2024]; Online First: 02 Apr, 2024. doi:10.5455/njppp.2024.14.12587202316032024

Harvard Style

Saha, M., Bandyopadhyay, . M., Mandal, . A., Ghosh, . A., Mandal, . P. & Chattopadhyay, . S. (2024) Bullous pemphigoid associated with the use of DPP4 inhibitors: A case series. Natl J Physiol Pharm Pharmacol, Online First: 02 Apr, 2024. doi:10.5455/njppp.2024.14.12587202316032024

Turabian Style

Saha, Manali, Mriganka Bandyopadhyay, Ananya Mandal, Arijit Ghosh, Pragnadyuti Mandal, and Suman Chattopadhyay. 2024. Bullous pemphigoid associated with the use of DPP4 inhibitors: A case series. National Journal of Physiology, Pharmacy and Pharmacology, Online First: 02 Apr, 2024. doi:10.5455/njppp.2024.14.12587202316032024

Chicago Style

Saha, Manali, Mriganka Bandyopadhyay, Ananya Mandal, Arijit Ghosh, Pragnadyuti Mandal, and Suman Chattopadhyay. "Bullous pemphigoid associated with the use of DPP4 inhibitors: A case series." National Journal of Physiology, Pharmacy and Pharmacology Online First: 02 Apr, 2024. doi:10.5455/njppp.2024.14.12587202316032024

MLA (The Modern Language Association) Style

APA (American Psychological Association) Style

Saha, M., Bandyopadhyay, . M., Mandal, . A., Ghosh, . A., Mandal, . P. & Chattopadhyay, . S. (2024) Bullous pemphigoid associated with the use of DPP4 inhibitors: A case series. National Journal of Physiology, Pharmacy and Pharmacology, Online First: 02 Apr, 2024. doi:10.5455/njppp.2024.14.12587202316032024

Author Login Reviewer Login About Publisher Editorial Policies Editorial Review Policy Peer Review Policy Editorial & Peer Review Process Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article


About National Journal of Physiology, Pharmacy and Pharmacology National Journal of Physiology, Pharmacy and Pharmacology is a monthly peer reviewed journal. The journal is having open access polic ... Read more. For best results, please use Internet Explorer or Google Chrome.	Contact Information Publisher publishernjppp@gmail.com Editorial query editornjppp1@gmail.com MOB - 8780040272